SR
Sarah Romano
Chief Financial Officer

Sarah Romano insider trades: Entero Therapeutics (ENTO) stock buys and sales

Chief Financial Officer, Entero Therapeutics Last trade Jan 6, 2025 54 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
11
Open-market trades
since 2017
4
Companies
last trade 2025

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Sarah reports to the SEC

Open-market buys and sales

11 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jan 6, 2025ENTO↓ Sell$465
Oct 9, 2024ENTO↓ Sell$212
Jul 2, 2024ENTO↓ Sell$664
Apr 1, 2024FWBI↓ Sell$317
Mar 15, 2024FWBI↓ Sell$6K
Jan 12, 2024FWBI↓ Sell$412
Oct 4, 2023FWBI↓ Sell$486
Jul 3, 2023FWBI↓ Sell$3K
Apr 3, 2023FWBI↓ Sell$5K
Jul 15, 2019EYEG↓ Sell$5K
Aug 15, 2017EYEG↑ Buy$10K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Sarah Romano's insider trades

Sarah Romano is Chief Financial Officer at Entero Therapeutics (ENTO). Since Aug 15, 2017, Sarah has reported 1 open-market purchase worth $10K and 10 sales worth $21K on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include shares withheld for taxes (30 filings), grants and awards (11 filings), other transactions (3 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ENTO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.